{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hematocrit: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hematocrit: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Leukocytes: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Leukocytes: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes: high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neutrophils: low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Neutrophils: high"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"PCI ranges for the hematology parameters were as follows: WBC count (low: \\<0.67 10\\^9 cells/L and high: \\>1.82 10\\^9 cells/L), neutrophil count (low: \\<0.83 10\\^9 cells/L), hemoglobin (high: \\>1.03 g/L in male, \\>1.13 g/L in female), hemocrit (high: \\>1.02 proportion of RBC in blood for male, \\>1.17 proportion of RBC in blood for female), platelet count (low: \\<0.67 10\\^9 cells/L and high: 1.57 10\\^9 cells/L), and lymphocytes (low: \\<0.81 10\\^9 cells/L).","groups":[{"description":"Participants received GSK3039294 600 mg, capsules, orally, under fed condition, QD for 7 days in cohort 3.","id":"OG000","title":"Part B: Cohort 3- GSK3039294 600 mg QD"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4a. The dose level was to be adjusted once during the 21 days. Cohort 4a was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG001","title":"Part B: Cohort 4a- GSK3039294"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4b. The dose level was to be adjusted once during the 21 days. Cohort 4b was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG002","title":"Part B: Cohort 4b- GSK3039294"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population. Data was not collected as study was terminated, due to safety reasons during conduct of Part B (end of Cohort 3) whereas Cohort 4a and 4b were not recruited in Part B.","reportingStatus":"POSTED","timeFrame":"Cohort 3 and 4: Up to Day 3","title":"Part B: Number of Participants With Emergent Hematology by PCI Criteria","type":"PRIMARY","unitOfMeasure":"Participants"}